methyl 5-[3-[(2R)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-oxopyrrolidin-1-yl]prop-1-ynyl]thiophene-2-carboxylate | 431990-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: methyl 5-[3-[(2R)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-oxopyrrolidin-1-yl]prop-1-ynyl]thiophene-2-carboxylate
• CAS: 431990-32-8
• 化学式: C₂₀H₂₉NO₄SSi
• 分子量: 407.606
• InChiKey: ZIXWMVGUJNUFSF-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  84.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 5-[3-[(2R)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-oxopyrrolidin-1-yl]prop-1-ynyl]thiophene-2-carboxylate 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 、 三氟乙酸吡啶 、 二甲基亚砜 作用下， 以 乙醇 、 苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats

  摘要：

  Heptanoic acid lactams. exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust bone anabolic effects when administered in vivo in rat models of osteoporosis. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.018
• 作为产物：
  描述：

  (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 在 copper(l) iodide 、 四(三苯基膦)钯 、 sodium hexamethyldisilazane 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 methyl 5-[3-[(2R)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-oxopyrrolidin-1-yl]prop-1-ynyl]thiophene-2-carboxylate
  参考文献：
  名称：

  Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats

  摘要：

  Heptanoic acid lactams. exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust bone anabolic effects when administered in vivo in rat models of osteoporosis. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.018